Editas Medicine Stock Today
| EDIT Stock | USD 1.22 0.02 1.61% |
Performance0 of 100
| Odds Of DistressOver 64
|
Editas Medicine is selling for under 1.22 as of the 18th of January 2025; that is 1.61 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 1.21. Editas Medicine has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 19th of November 2024 and ending today, the 18th of January 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of February 2016 | Category Healthcare | Classification Health Care |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 82.55 M outstanding shares of which 18.21 M shares are currently shorted by private and institutional investors with about 5.7 trading days to cover. More on Editas Medicine
Moving together with Editas Stock
Moving against Editas Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Editas Stock Highlights
| CEO President | Gilmore MD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsEditas Medicine can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Editas Medicine's financial leverage. It provides some insight into what part of Editas Medicine's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Editas Medicine (EDIT) is traded on NASDAQ Exchange in USA. It is located in 11 Hurley Street, Cambridge, MA, United States, 02141 and employs 265 people. Editas Medicine is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 102.36 M. Editas Medicine conducts business under Biotechnology sector and is part of Health Care industry. The entity has 82.55 M outstanding shares of which 18.21 M shares are currently shorted by private and institutional investors with about 5.7 trading days to cover.
Editas Medicine currently holds about 452.56 M in cash with (132.18 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Editas Medicine Probability Of Bankruptcy
Ownership AllocationEditas Medicine holds a total of 82.55 Million outstanding shares. The majority of Editas Medicine outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Editas Medicine to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Editas Medicine. Please pay attention to any change in the institutional holdings of Editas Medicine as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Editas Ownership Details
Editas Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Pictet Asset Manangement Sa | 2024-09-30 | 1.2 M | |
| Two Sigma Advisers, Llc | 2024-09-30 | 1.1 M | |
| Woodline Partners Lp | 2024-09-30 | 900.4 K | |
| Ubs Asset Mgmt Americas Inc | 2024-09-30 | 897.5 K | |
| Bank Of America Corp | 2024-09-30 | 882.2 K | |
| Jane Street Group Llc | 2024-09-30 | 863.8 K | |
| Jpmorgan Chase & Co | 2024-09-30 | 771.2 K | |
| Northern Trust Corp | 2024-09-30 | 703.8 K | |
| Stifel Financial Corp | 2024-09-30 | 624.9 K | |
| Blackrock Inc | 2024-09-30 | 8 M | |
| Vanguard Group Inc | 2024-09-30 | 6.7 M |
Editas Medicine Historical Income Statement
Editas Stock Against Markets
Editas Medicine Corporate Management
| Bruce Eaton | Exec Officer | Profile | |
| Cristi Barnett | Corporate Relations | Profile | |
| Charlene JD | Executive Counsel | Profile | |
| Michelle Robertson | Principal CFO | Profile |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.